Eli Lilly (NYSE:LLY) just gave its newest drug a second act. Foundayo, which CEO David Ricks calls “the only approved GLP-1 pill that can be taken any time of day, without food and water restrictions,” significantly improved obstructive sleep apnea severity in the Phase 3 ATTAIN-OSA trial, with a U.S. FDA submission planned by the end of 2026. Foundayo sales already rose from $98 million in Q2 to $184 million in Q3.

Shares are up 28.29% year-to-date and 47.28% over the past year. Ricks put it simply: “We are in the middle of the largest new category expansion in the history of the pharmaceutical industry, and Lilly is leading that.” Lilly needs a 31% gain to hit $1,800 per share in 2027.

Wall Street’s Average Target Lags Its Most Bullish Call

The consensus target of $1,453.40 implies only about 6% upside from $1,372. The high end is moving, though. Jefferies raised its target to $1,700 from $1,610, a Street-high, citing larger-than-expected international obesity market potential.

Analysts expect 2027 EPS of $50.1525, up from $35.3522 in 2026, about 42% growth. Ninety days ago, that 2027 figure was $45.0802.

Can Eli Lilly Really Hit $1,800? Here’s the Math

At $1,372, Lilly trades at 27x 2027 earnings. At $1,800, that multiple would be 36x, above the S&P 500’s 21-23x. That premium is justified for earnings growing near 42%, and Lilly has beaten estimates for five consecutive quarters, including Q3 EPS of $7.48 versus $6.67 expected.

What Could Push Eli Lilly to $1,800?

• Foundayo in diabetes: Lilly expects regulatory action in type 2 diabetes in Q4, and Ricks noted “roughly half the volume of GLP-1s is in diabetes.”
• Global rollout: Foundayo is under review in more than 40 additional countries, with a broad launch targeted for 2027.
• Retatrutide: A BLA submission is planned for Q1 2027 after it delivered 20% to 21% weight loss versus 9.4% for semaglutide.
• Medicare access: The Bridge Program opened obesity coverage to approximately 20 million seniors.
• Untapped demand: The CFO said Lilly reaches “one out of 10 patients” in the U.S.

Eli Lilly Has Topped 31% in Each of the Past Five Years

The 31% gain needed for $1,800 is routine by recent standards. Lilly returned 66.1% in 2021, 34.2% in 2022, 60.9% in 2023, 33.3% in 2024 and 40.2% in 2025. At a $1.22 trillion market cap, each gain demands more absolute dollars, but the run shows consistent compounding.

$1,800 Is a Stretch, but the Blueprint Is Clear

Reaching $1,800 requires a 31% gain in 2027. Rising estimates, a beat run and new Foundayo indications support the case. Hurdles include a 15% decline in realized prices and approximately $2 billion of 2026 one-time items that won’t repeat. Lilly will issue 2027 guidance in January, a near-term test for the thesis. Returns at this level shouldn’t be expected every year, but we’ve outlined the plan for how Eli Lilly could see outsized returns in 2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.